April 2, 2019 Clinical Research/Diagn. Lab Top-10

PerkinElmer Genomics Introduces Physician-Ordered Genetic Screening Test for Proactive Health Management

Available in Helix’s DNA marketplace, GenePrism: Actionable Insights is the first clinical-grade DNA test available to health individuals that analyzes all 59 medically actionable genes identified by the American College of Medical Genetics and Genomics WALTHAM, Massachusetts – April 2, 2019 – Today, in collaboration with Helix, PerkinElmer, Inc., a global leader committed to innovating... Read more

April 1, 2019 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10

New Expanded Analytical Instrument Portfolio of U.S. FDA Class I Medical Devices for Clinical Diagnostic Laboratories

Palm Springs, CA – MSACL US 2019 – (April 1, 2019)– Thermo Fisher Scientific announces the expansion of its portfolio of analytical instruments for clinical diagnostic laboratories with the addition of three systems now listed as Class I medical devices with the United States Food and Drug Administration (U.S. FDA). The portfolio now offers clinical diagnostic laboratories... Read more

April 1, 2019 Clinical Research/Diagn. M&A, Partnerships

NanoString and Abcam Enter Commercial Partnership to Provide Expanded Menu of Antibodies for GeoMx Digital Spatial Profiler

— Abcam to Develop Conjugated FFPE IHC Validated Antibodies Compatible with the GeoMx DSP — SEATTLE and CAMBRIDGE, UK, April 01, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a commercial agreement with Abcam plc (AIM:ABC), a global innovator in life science reagents and tools, for the manufacture... Read more

April 1, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Lab Top-10 Product Launch

New Expanded Analytical Instrument Portfolio of U.S. FDA Class I Medical Devices for Clinical Diagnostic Laboratories

New Expanded Analytical Instrument Portfolio of U.S. FDA Class I Medical Devices for Clinical Diagnostic Laboratories Thermo Scientific Medical Device portfolio provides an extensive range of chromatography and mass spectrometry instruments for laboratory development test optimization PALM SPRINGS, Calif., April 1, 2019 /PRNewswire/ — MSACL US 2019 – Thermo Fisher Scientific announces the expansion of its portfolio... Read more

March 28, 2019 Clinical Research/Diagn. Liq. Handling & Robotics PR/Corporate

Quanterix Appoints Amol Chaubal as Chief Financial Officer

MARCH 28, 2019 Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth and scaling  LEXINGTON, Mass. – March 28, 2019 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named Amol Chaubal to the position of... Read more

March 28, 2019 Clinical Research/Diagn. Mass Spectrometry Product Launch

Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry

The new standard in immune profiling for advancing translational and clinical research of immune-mediated diseases SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the introduction of the Maxpar® Direct™ Immune Profiling System. Setting the new standard in immune... Read more

March 25, 2019 Clinical Research/Diagn. Life Science Tools PR/Corporate

NanoString Technologies Announces Closing of Public Offering of 5,175,000 Shares of Common Stock Including Exercise in Full of Option to Purchase Additional Shares

SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $23.00 per share pursuant to its shelf registration statement. NanoString sold 3,175,000 shares of... Read more

March 22, 2019 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal Liq. Handling & Robotics

Bruker Announces Improved Assay for Tuberculosis Diagnostics in Novel Liquid Array™ Format for Improved Multiplexing

– Expanded FluoroType™ MTBDR 2.0 Liquid Array molecular assay with CE-IVD mark provides highly differentiated tuberculosis (TB) detection and antibiotic resistance testing – Novel FluoroCycler™ XT PCR system with CE-IVD mark enables new Liquid Array format NEHREN, Germany, March 22, 2019 /PRNewswire/ — In time for the World Tuberculosis (TB) Day 2019 on Sunday, March... Read more

March 21, 2019 Clinical Research/Diagn. PR/Corporate

Abcam wins the UK-China Business award

March 21, 2019- China represents an important market for us and we are thrilled to announce that Abcam has been chosen as the winner of the Cambridge Business Weekly UK-China Business Award. This new award category, which acknowledges the most effective ambassador for UK/China trade and trust over the last 12 months, has been jointly... Read more

March 19, 2019 Clinical Research/Diagn. Life Science Tools PR/Corporate

NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock

SEATTLE, March 19, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $23.00 per share pursuant to its shelf registration statement. NanoString will sell 2,500,000 shares of common... Read more